Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

Defining value: has anyone asked the patient?

The real-world challenges they face give patients unique views on 'value'

Bristol-Myers Squibb (BMS) building

Speedy NICE appraisal backs BMS’ Opdivo/Yervoy combination

But HTA body doesn't find Roche's Cotellic/Zelboraf cost-effective

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

- PMLiVE

Vertex’ cystic fibrosis drug too costly, says NICE

£104,000 per patient price tag is "too high" for the drug’s “modest” short term benefit

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

The death of deference

We are entering an age when authority matters less

- PMLiVE

Boyds expands regulatory affairs team

Céline Courtay-Cahen joins the pharma and biotech consultancy

Dr Alan Joslyn becomes president and CEO of Oragenics

He will also serve on the company’s board of directors

- PMLiVE

Boehringer Ingelheim launches ‘gamified’ COPD initiative

Programme aims to encourage and reward disease management

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

- PMLiVE

The value of early asset development and commercialisation

Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets...

UK flag

UK biotech beats fundraising records in 2015, says BIA

Record-breaking amount accounts for a third of all EU biotech venture finance last year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links